Inhibits IL-8 production leading to tumor reduction and susceptibility to chemotherapy. IL-8 via its cognate receptors, CXCR1 and CXCR2, may regulate CSC activity. Undergoing phase I clinical trials for breast cancer. Here, CXCR2 is linked to neoplasm.